Management Team


Øystein Soug , Chief Executive Officer

20 years in international banking and industry, the last six of which as CFO of Algeta ASA and was the former CFO of Targovax ASA.

Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014. Prior to joining Algeta in 2008 Mr. Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division.

Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. Mr. Soug received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997.


Anne Kirsti Aksnes , Vice President, Clinical Development

More than 35 years of experience within clinical research and clinical development in the pharmaceutical/biotech industry.

Previously, she was VP Clinical Research in Algeta ASA (now Bayer AS), where she had a key role in the strategic, scientific and clinical development as well as in medical communications. She also holds a PhD in medicine from Karolinska Institute.


Magnus Jaderberg , Chief Medical Officer

A pharmaceutical physician with more than 30 years in various R&D functions including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management.

Experienced in all phases of clinical research including clinical pharmacology, dose finding, registration, post-launch product differentiation and surveillance. His immunotherapy expertise includes several compounds including Yervoy (ipilimumab). Prior to joining Oncos, Magnus held roles at national, European and global level at GSK, Pharmacia, Wyeth and most recently as Chief Medical Officer, Bristol Myers Squibb (Europe).

Qualified in medicine at Karolinska Institute, Stockholm, Sweden, and is a fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom, and honorary lecturer in drug development at King’s College.


Torbjørn Furuseth , Chief Financial Officer

Experienced life science executive and medical doctor with background from management consulting.

Torbjørn is an experienced executive with a broad background within life science. He joins from the clinical stage immune-oncology company Lytix Biopharma, where he has served as CFO and conducted several financing rounds. Prior to this, he was EVP Innovation at Aker BioMarine, where he established and led the innovation department. Torbjørn also brings six years’ experience as a management consultant at McKinsey & Company, where he served several pharma and healthcare clients.

Torbjørn is a Medical Doctor from Norwegian University of Science and Technology (NTNU).


Erik Digman Wiklund , Chief Business Officer

Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research.

Erik trained as a scientist specializing in cancer epigenetics research, and he holds a PhD in molecular biology. After completing a postdoctoral fellowship, he transitioned to management consulting and joined the Pharma and Healthcare practice of McKinsey & Company. For the past 5 years he has held several positions in Norwegian biotech companies, including at Alegta, which developed and launched Xofigo. He joined Targovax as CFO in 2017, and has recently transitioned into the CBO position.


Berit Iversen , Vice President, Head of CMC

30 years of experience within Research & Development in the pharmaceutical and biotech industry.

Managing positions within CMC, analytical sciences, Quality Control and Quality Assurance. Global cross functional development experience in pharma from preclinical through to regulatory approval. Experience from GE Healthcare, Invitrogen Dynal (now Thermo Fischer) and Lytix Biopharma.